ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
Returns on capital
ArriVent BioPharma, Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-54.1%
avg -55.5%
ROIC
-57.8%
avg -37.2%
ROA
-49.9%
avg -52.4%
Analysis
ROA is currently the strongest return metric at -49.9% versus its period average of -52.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Zhengbin Yao | Co-Founder, Chairman, President & Chief Executive Officer | USD 968.67K | 60 | 550.00K | 1.18% |
Stuart Lutzker | Co-Founder, President of Research & Development and Director | USD 777.35K | 65 | 150.00K | 0.32% |
Winston Kung | Chief Financial Officer & Treasurer | USD 752.7K | 50 | 140.00K | 0.30% |
Robin LaChapelle | Co-Founder & Chief Operating Officer | USD 586.45K | 53 | 0 | <0.01% |
James Paul Kastenmayer | General Counsel & Secretary | — | 54 | 130.00K | 0.28% |
Brent S. Rice | Chief Commercial Officer | — | 60 | — | — |
Yang Wang | Chief Technology Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$12.98M
Net Transaction Value
−$12.98M
Net selling
Most Active
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Dec 10, 25Dec 10, 2025 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. Indirect | Sell | $13M$12,983,320.35 |
Summary
Insiders reported 0 buys worth $0.00 and 1 sells worth $12.98M over the last 12 months. That adds up to net selling of $12.98M. HILLHOUSE INVESTMENT MANAGEMENT, LTD. was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does ArriVent BioPharma, Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about AVBP's management, answered from reported figures.
Who manages AVBP?
ArriVent BioPharma, Inc. Common Stock (AVBP) lists 7 active executives. The top listed executive is James Paul Kastenmayer, General Counsel & Secretary.
Are AVBP insiders buying or selling?
Recent insider activity shows net buying of $66.71M.
Continue the stock analysis
Jump to another research area for this company.